VBWG

About VBWG

Mission Statement

To improve the cardiovascular health of patients by providing a forum for the review, exchange, and assimilation of findings from vascular biology research for dissemination to the clinical medicine community.
 

Background

VBWG was conceived in 1994 to unify the broad spectrum of vascular science that is driving the advances related to prevention and management of coronary artery disease. The VBWG serves as a forum for the periodic review, exchange, and assimilation of findings from vascular biology research for dissemination to the clinical medicine community. A key function of the Vascular Biology Working Group is to facilitate a consensus on what implications recent research findings have for present and future practices in patient care.
 

Disclaimer

The editorial content of this web site express the views of the individual contributors and does not necessarily reflect the views or recommendations of the University of Florida College of Medicine or the Foundation Sponsors. The indications and dosages of drugs discussed in these pages and discussions may vary from those approved by the Food and Drug Administration(FDA). The reader is advised to consult the full prescribing information for each medication prior to use.
 

Accreditation

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The ACCME certifies that the University of Florida College of Medicine has fulfilled the accreditation requirements for Accreditation with Commendation.

Program Chairman
Carl J. Pepine, MD, MACC
Professor of Medicine
Division of Cardiovascular Medicine
University of Florida College of Medicine
Gainesville, Florida
Chairman, Vascular Biology Working Group

Program and CME Coordinator
Eileen Handberg, PhD, ARNP-BC
Associate Professor of Medicine
Director of Clinical Programs
Division of Cardiovascular Medicine
University of Florida College of Medicine
Gainesville, Florida
 

Educational Objectives

To review new data on the pathophysiology of coronary artery disease and its relevance to treatment strategies and outcomes.
To understand the pharmacologic and clinical rationale for various treatment options in the CAD patient.
To develop a consensus on practical guidelines for day-to-day management of the coronary artery disease patient.
 

Funding

During the past twelve months educational support has been provided by Actelion, Amarin, Amgen, AstraZeneca, Baxter, Bristol Myers Squibb, Catabasis, Cytori, Daiichi Sankyo, Esperion, Genentech, Isis, Lilly, NeoStem, Pfizer, Regeneron, Sanofi, and United Therapeutics.